acute myeloid leukaemia Archives -

Pleco Therapeutics has closed a first-round financing, raising just over €17 million that it says will fund the

Pleco raises €17m for tumour microenvironment drug

https://pharmaphorum.com/news/pleco-raises-e17m-for-tumour-microenvironment-drug/

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Phil Taylor acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata 0 Comment

Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

https://pharmaphorum.com/news/eha-survival-data-sets-daiichi-sankyos-quizartinib-back-on-track/

News/ News/ News/ Oncology/ Sales and Marketing

FDA clears new first-line use for Servier’s Tibsovo in AML

Phil Taylor acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo 0 Comment

Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma’s oncology business

FDA clears new first-line use for Servier’s Tibsovo in AML

https://pharmaphorum.com/news/fda-clears-new-first-line-use-for-serviers-tibsovo-in-aml/

News/ News/ News/ Oncology/ R&D

Nkarta leaps on early CAR-NK data in blood cancers

Phil Taylor acute myeloid leukaemia, car-nk, cell therapy, Haematology, immuno-oncology, lymphoma, Nkarta, Oncology 0 Comment

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be

Nkarta leaps on early CAR-NK data in blood cancers

https://pharmaphorum.com/news/nkarta-leaps-on-early-car-nk-data-in-blood-cancers/

Digital/ News/ News

Blue Note leukaemia DTx gets FDA breakthrough tag

Phil Taylor acute myeloid leukaemia, anxiety, Blue Note Therapeutics, depression, digital, digital health, Oncology 0 Comment

A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device

Blue Note leukaemia DTx gets FDA breakthrough tag

https://pharmaphorum.com/news/blue-note-leukaemia-dtx-gets-fda-breakthrough-tag/

News/ News/ Oncology

BMS cuts $3.15bn deal with Century for cancer cell therapies

Phil Taylor acute myeloid leukaemia, Bristol-Myers Squibb, cell therapy, Century Therapeutics, Haematology, immuno-oncology, multiple myeloma, Oncology 0 Comment

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company’s pipeline at the virtual JP

BMS cuts $3.15bn deal with Century for cancer cell therapies

https://pharmaphorum.com/news/bms-cuts-3-15bn-deal-with-century-for-cancer-cell-therapies/

News/ News/ Oncology

ASH: Servier’s Tibsovo poised for first-line used in AML

Phil Taylor acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo 0 Comment

Servier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for

ASH: Servier’s Tibsovo poised for first-line used in AML

https://pharmaphorum.com/news/ash-serviers-tibsovo-poised-for-first-line-used-in-aml/

News/ News/ Oncology

Kura hit as FDA slaps partial hold on leukaemia trial

Phil Taylor acute myeloid leukaemia, Kura Oncology, menin inhibitor, novel targeted cancer treatments, Oncology 0 Comment

Share in Kura Oncology have come under pressure after a patient death in a clinical trial of the

Kura hit as FDA slaps partial hold on leukaemia trial

https://pharmaphorum.com/news/kura-hit-as-fda-slaps-partial-hold-on-leukaemia-trial/

News/ News/ Oncology

Gamble by Takeda on unproven cancer mechanism draws a blank

Phil Taylor acute myeloid leukaemia, blood cancer, Haematology, Oncology, Takeda 0 Comment

Takeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor –

Gamble by Takeda on unproven cancer mechanism draws a blank

https://pharmaphorum.com/news/takeda-gamble-on-unproven-cancer-mechanism-draws-a-blank/

Trending

acute myeloid leukaemia

Login